Physician profile
Mark S Dennis
NPI 1801866215
$2,127.38
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $858 · 2020: $392 · 2021: $367 · 2022: $330 · 2023: $153 · 2024: $27.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $179.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $375.97 | 2019-2023 | Belbuca |
| Abbvie INC. | $230.63 | 2021-2023 | Botox |
| Teva Pharmaceuticals USA, INC. | $208.64 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $182.01 | 2019-2022 | |
| Vertiflex, INC. | $174.33 | 2019 | |
| Sentynl Therapeutics, INC. | $165.12 | 2019-2020 | |
| Lilly USA, LLC | $162.53 | 2019-2021 | |
| Boston Scientific Corporation | $81.32 | 2020-2021 | |
| Abbott Laboratories | $64.78 | 2019-2020 | |
| Pfizer INC. | $60.20 | 2019-2021 | |
| Medtronic USA, INC. | $47.39 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $47.18 | 2023 | Spravato |
| Grt US Holding, INC. | $38.87 | 2020-2021 | |
| Allergan, INC. | $36.65 | 2020-2021 | |
| Orthogenrx INC. | $30.92 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $27.60 | 2020 | |
| Virtus Pharmaceuticals LLC | $27.10 | 2024 | Levorphanol Tartrate |
| Lundbeck LLC | $23.10 | 2022 | |
| Daiichi Sankyo INC. | $21.06 | 2019 | |
| Amgen INC. | $18.64 | 2020 | |
| Redhill Biopharma INC. | $17.82 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.79 | 2022 | |
| Horizon Therapeutics Plc | $15.34 | 2021 | |
| Forte Bio-Pharma LLC | $13.77 | 2023 | Prolate, Nalocet |
| Medtronic, INC. | $13.33 | 2023 | Synchromedii |
| Biohaven Pharmaceuticals, INC. | $12.79 | 2021 | |
| Vertical Pharmaceuticals, LLC | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dennis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.